EMERYVILLE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. today announced that it will webcast an investor briefing on Wednesday, September 30, 2009, beginning at 10:00 a.m. Eastern Time. Speakers will review clinical data for Nexavar in breast cancer presented at the 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress in Berlin.
http://www.onyx-pharm.com/view.cfm/32/Event-Calendar
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyx-pharm.com.
SOURCE Onyx Pharmaceuticals, Inc.
CONTACT: Alex Santos of Onyx Pharmaceuticals, Inc., +1-510-597-6504
Web site: http://www.onyx-pharm.com/
